Cabozantinib to Treat Recurrent Liver Cancer Post Transplant — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant — Stella

Recruiting

Back to Hepatocellular Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Canada

Princess Margaret Cancer Centre, Toronto, Ontario

Key details

Phase

Safety & dosing

Sponsor

University Health Network, Toronto

Collaborators

Ipsen

Enrollment target

~20 participants

Started

August 2020

Primary completion

June 2026

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov